Browsing Centre for Haemato-Oncology by Title

THE ADDITION OF RITUXIMAB TO CODOX-M/IVAC CHEMOTHERAPY IN THE TREATMENT OF BURKITT LYMPHOMA IS SAFE AND IS ASSOCIATED WITH INCREASED EFFICACY IN THE HIV POSITIVE POPULATION

Alwan, F; He, A; Montoto, S; Kassam, S; Mee, M; Burns, F; Edwards, S; Wilson, A; Tenant-Flowers, M; Marcus, R (2014-06-01)

The Ageing Brain: Effects on DNA Repair and DNA Methylation in Mice

Langie, SAS; Cameron, KM; Ficz, G; Oxley, D; Tomaszewski, B; Gorniak, JP; Maas, LM; Godschalk, RWL; van Schooten, FJ; Reik, W (2017-02)

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Bachanova, V; Burns, LJ; Wang, T; Carreras, J; Gale, RP; Wiernik, PH; Ballen, KK; Wirk, B; Munker, R; Rizzieri, DA (2015-02)

Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway

Edelmann, J; Britton, DJ; Vilventhraraja, E; Dokal, A; Holzmann, K; Cragg, MC; Braun, A; Cutillas, P; Gribben, JG (2018-11-29)

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.

Maybury, B; Cook, G; Pratt, G; Yong, K; Ramasamy, K (2016-11)

Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved ...

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

Snowden, JA; Hawkey, C; Hind, D; Swaby, L; Mellor, K; Emsley, R; Mandefield, L; Lee, E; Badoglio, M; Polge, E (2019-05-31)

Autophagy mediates degradation of nuclear lamina

Dou, Z; Xu, C; Donahue, G; Shimi, T; Pan, J-A; Zhu, J; Ivanov, A; Capelll, BC; Drake, AM; Shah, PP (2015-11-05)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors

Korfi, K; Smith, M; Swan, J; Somervaille, TCP; Dhomen, N; Marais, R (2016-04)

Blocking Autophagy Prevents Bortezomib-Induced NF-kappa B Activation by Reducing I-kappa B alpha Degradation in Lymphoma Cells

Jia, L; Gopinathan, G; Sukumar, JT; Gribben, JG (2012-02-29)

Cancer Burden Is Controlled by Mural Cell-beta 3-Integrin Regulated Crosstalk with Tumor Cells

Wong, P-P; Munoz-Felix, JM; Hijazi, M; Kim, H; Robinson, SD; De Luxan-Delgado, B; Rodriguez-Hernandez, I; Maiques, O; Meng, Y-M; Meng, Q (2020-06-11)

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia

Liu, FT; Giustiniani, J; Farren, T; Jia, L; Bensussan, A; Gribben, JG; Agrawal, SG (2010-04-15)

Cdk7: open questions beyond the prevailing model.

Ganuza, M; Santamaría, D (2012-10-01)

Cellular Therapy in Follicular Lymphoma Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy

Okosun, J; Montoto, S (2020-08)

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients

Caldwell, L; Bapat, A; Drumright, LN; Lambourne, J; Jimenez-England, FG; Aries, J; Eccersley, L; Hallam, S; Montoto, S; Oakervee, H (2021-12-04)

Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling.

Balic, A; Sørensen, MD; Trabulo, SM; Sainz, B; Cioffi, M; Vieira, CR; Miranda-Lorenzo, I; Hidalgo, M; Kleeff, J; Erkan, M (2014-07)

Pancreatic ductal adenocarcinoma is one of the deadliest carcinomas and is characterized by highly tumorigenic and metastatic cancer stem cells (CSC). CSCs evade available therapies, which preferentially target highly ...

CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantation

Lawson, H; van de Lagemaat, LN; Barile, M; Tavosanis, A; Durko, J; Villacreces, A; Bellani, A; Mapperley, C; Georges, E; Martins-Costa, C (2021-11-09)

Clinical outcome of coronavirus disease 2019 in haemato-oncology patients

Aries, JA; Davies, JK; Auer, RL; Hallam, SL; Montoto, S; Smith, M; Sevillano, B; Foggo, V; Wrench, B; Zegocki, K (2020-07)

CLOFARABINE IN COMBINATION WITH HIGH-DOSE CYTARABINE AND LIPOSOMAL DAUNORUBICIN IN PEDIATRIC AML: RESULTS OF A PHASE 1 COMBINATION STUDY BY THE ITCC CONSORTIUM

Zwaan, CM; Dworzak, M; Klingebiel, T; Roessig, C; Leverger, G; Stary, J; de Bont, ES; Niemeyer, CM; Kaspers, GJ; Bertrand, Y (2014-12)

Clones assemble! The clonal complexity of blood during ontogeny and disease.

Ganuza, M; Hall, T; Obeng, EA; McKinney-Freeman, S (2020-03)

Hematopoietic stem and progenitor cells (HSPCs) govern the daily expansion and turnover of billions of specialized blood cells. Given their clinical utility, much effort has been made toward understanding the dynamics of ...

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.

Di Tullio, A; Rouault-Pierre, K; Abarrategi, A; Mian, S; Grey, W; Gribben, J; Stewart, A; Blackwood, E; Bonnet, D (2017-11-22)

Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances ...